文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症重症综合管理与镇静镇痛

系统性硬化症相关间质性肺病合并与不合并肺动脉高压对生存的影响:德国系统性硬化症网络大型队列研究

Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
PubMed 文献 · Chest · 2023-08-13
一句话结论在德国系统性硬化症网络队列中,间质性肺病合并肺动脉高压的生存最差,5年总生存无肺受累者为96.4%。

该研究基于德国系统性硬化症网络登记库,纳入3257例系统性硬化症患者,平均随访3.45±1.63年,旨在比较间质性肺病合并肺动脉高压(ILD-PH)、不合并肺动脉高压的间质性肺病(ILD)、肺动脉高压(PAH)及无肺受累患者的生存差异。基线时ILD患病率为34.5%,无ILD的PH患病率为4.5%;随访结束时47.6%有ILD,15.2%有ILD-PH,6.5%有PAH。无肺受累者5年总生存为96.4%,ILD不合并PH、PAH及ILD-PH患者间生存差异显著,ILD-PH最差。女性(HR 0.3)、较高BMI(HR 0.9)和较高一氧化碳弥散量(HR 0.98)与较低死亡风险相关。

要点

  • 随访结束时47.6%的系统性硬化症患者有ILD,15.2%有ILD-PH,6.5%有PAH;ILD-PH的5年生存最差。
  • 无肺受累的系统性硬化症患者5年总生存为96.4%,ILD不合并PH、PAH和ILD-PH患者间总体生存差异显著。
  • 女性(HR 0.3)、较高BMI(HR 0.9)和较高一氧化碳弥散量(HR 0.98)与较低死亡风险相关。
  • 弥漫皮肤型系统性硬化症中间质性肺病更常见(57.3%),而PAH在系统性硬化症亚型间无显著差异。
  • 基线时ILD患病率为34.5%,无ILD的PH患病率为4.5%。

适用人群与场景

  • 德国系统性硬化症网络登记库中登记的5831例系统性硬化症患者,其中3257例纳入分析,平均随访3.45±1.63年。

研究设计与关键结果

  • 研究类型为基于德国系统性硬化症网络登记库的队列研究,纳入3257例系统性硬化症患者,平均随访3.45±1.63年。
  • 基线时ILD患病率34.5%,无ILD的PH患病率4.5%;随访结束时ILD 47.6%,ILD-PH 15.2%,PAH 6.5%。
  • ILD在弥漫皮肤型中更常见(57.3%),PAH在系统性硬化症亚型间无显著差异。
  • PAH、ILD-PH与ILD不合并PH三组基线特征在诊断年龄、性别、系统性硬化症亚型、抗体状态、FVC、一氧化碳弥散量和治疗方面差异显著。
  • 无肺受累患者5年总生存为96.4%,ILD不合并PH、PAH和ILD-PH患者间总体生存差异显著,ILD-PH最差。
  • 女性(HR 0.3)、较高BMI(HR 0.9)和较高一氧化碳弥散量(HR 0.98)与较低死亡风险相关。

证据类型、等级与局限

  • 证据类型:基于登记库的队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐;作者认为ILD是系统性硬化症最常见的肺部受累,ILD合并PH与最差的生存相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Pulmonary involvement is the leading cause of death in systemic sclerosis (SSc) and may manifest as interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), or in combination of both (ILD with pulmonary hypertension [ILD-PH]). The aim of this analysis was to determine prevalence, clinical characteristics, and survival of these different forms within the registry of the German Network for Systemic Sclerosis.

RESEARCH QUESTION: Does SSc-associated ILD-PH or ILD without PH affect survival differently, and are there any risk factors that have an additional impact?

STUDY DESIGN AND METHODS: Clinical data of 5,831 patients with SSc were collected in the German Network for Systemic Sclerosis registry. Kaplan-Meier estimates were used to compare overall survival in patients with SSc-associated ILD-PH and ILD without PH with patients without pulmonary involvement and those with PAH. The Cox proportional hazard model was used to analyze the influence of pulmonary involvement and other potential predictors on patient survival.

RESULTS: Clinical data of 3,257 patients with a mean follow-up time of 3.45 ± 1.63 years have been included in our analysis. At baseline, ILD was present in 34.5%, whereas PH without ILD had a lower prevalence with 4.5%. At the end of follow-up, 47.6% of patients with SSc had ILD, 15.2% had ILD-PH, and 6.5% had PAH. ILD was more frequent in the diffuse cutaneous form (57.3%), whereas PAH did not differ significantly between SSc subtypes. Significant differences in baseline characteristics between PAH vs ILD-PH vs ILD without PH were found for age at diagnosis, sex, SSc subsets, antibody status, FVC, diffusing capacity of the lung for carbon monoxide, and therapy. Overall survival at 5 years was 96.4% for patients without pulmonary involvement and differed significantly between patients with ILD without PH, PAH, and being worst in patients with ILD-PH. Female sex (hazard ratio [HR], 0.3), higher BMI (HR, 0.9), and higher diffusing capacity of the lung for carbon monoxide values (HR, 0.98) were associated with a lower mortality risk.

INTERPRETATION: ILD is the most prevalent pulmonary involvement in SSc, whereas the combination of ILD and PH is associated with the most detrimental survival.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Moinzadeh P, Bonella F, Oberste M, et al. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis. Chest. 2023. PMID: 37582424. doi:10.1016/j.chest.2023.08.013

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。